肾上腺素β2受体激动药与抗胆碱能药物治疗慢性阻塞性肺疾病的研究进展

Progress of β2 adrenoceptor agonist and anticholinergic agent for COPD

慢性阻塞性肺疾病(COPD)是全球研究的热点,发病率和死亡率均较高,其治疗目标是改善症状和降低急性加重风险。最新版COPD全球倡议依旧将长效肾上腺素β2受体激动药(LABA)和长效抗胆碱能药物(LAMA)作为基础治疗药物,而随着新型支气管扩张药物如以茚达特罗、噻托溴铵为代表的LABA、LAMA及LABA+LAMA组合制剂等品种的增多,临床也面临越来越多的选择。近年来,采用LABA+LAMA组合疗法在COPD治疗中所占比重越来越大,在缩短起效时间、改善第一秒用力呼气容积和呼吸困难症状等方面也具有优势。

Chronic obstructive pulmonary disease(COPD)is a hot spot in global research and has the characteristics of high incidence and mortality.The goal of pharmacologic therapy for COPD is to improve symptoms and reduce the risk of acute exacerbations.Long-actingβ2 adrenoceptor agonists(LABA)and long-acting antimuscarinic antagonists(LAMA)still are the cornerstone of pharmacologic treatment in the latest version of global initiative for COPD.Clinicians are faced with an increasingly choice regarding the bronchodilator such as the LABA,LAMA alone or LABA combined with LAMA for patients with COPD given the number of new drugs.In recent years,the combination therapy of LABA+LAMA has become more and more important in the treatment of COPD,and it has more advantages in shortening the onset time,improving the forced expiratory volume in one second and the symptoms of severe dyspnea.